{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:23Z","timestamp":1794013283130,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005241","name":"Institut de Recherche Clinique De Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinbiochem.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T02:22:37Z","timestamp":1659666157000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study"],"prefix":"10.1016","volume":"109-110","author":[{"given":"Samuel","family":"Doiron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Boll\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcl.2018.08.006","article-title":"Nephrotic syndrome","volume":"66","author":"Wang","year":"2019","journal-title":"Pediatr. Clin. North Am."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2022.08.002_b0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfz108","article-title":"Protein convertase subtilisin\/kexin type 9 biology in nephrotic syndrome: implications for use as therapy","volume":"35","author":"Busuioc","year":"2020","journal-title":"Nephrol. Dial Transplant."},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.08.002_b0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","article-title":"Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome","volume":"323","author":"Joven","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.08.002_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin","year":"2018","journal-title":"Drugs."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.clinbiochem.2022.08.002_b0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.clinbiochem.2022.08.002_b0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2022.08.002_b0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.atherosclerosis.2012.11.009","article-title":"Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment","volume":"226","author":"Kwakernaak","year":"2013","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.clinbiochem.2022.08.002_b0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","article-title":"Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study","volume":"63","author":"Jin","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.clinbiochem.2022.08.002_b0060","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: Clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/0886022X.2020.1756846","article-title":"Correlation between plasma proprotein convertase subtilisin\/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome","volume":"42","author":"Shen","year":"2020","journal-title":"Ren Fail."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.08.002_b0075","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.kint.2020.06.045","article-title":"Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome","volume":"98","author":"Molina-Jijon","year":"2020","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.clinbiochem.2022.08.002_b0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2017.0027","article-title":"Association between plasma proprotein convertase subtilisin\/kexin type 9 and the presence of metabolic syndrome in a predominantly rural-based sub-saharan african population","volume":"15","author":"Paquette","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"6","key":"10.1016\/j.clinbiochem.2022.08.002_b0085","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.kint.2021.01.023","article-title":"Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner","volume":"99","author":"Shrestha","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacl.2016.10.005","article-title":"Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism","volume":"11","author":"Morena","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-017-0644-0","article-title":"Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report","volume":"18","author":"Awanami","year":"2017","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2022.08.002_b0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ekir.2020.09.046","article-title":"Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome","volume":"6","author":"Jatem","year":"2020","journal-title":"Kidney Int. Rep."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022001904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912022001904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:10:32Z","timestamp":1762114232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912022001904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"alternative-id":["S0009912022001904"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.08.002","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}